Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Amgen to present oncology portfolio results at ESMO Congress

Amgen to present oncology portfolio results at ESMO Congress

New approach method could simplify study and treatment of human diseases

New approach method could simplify study and treatment of human diseases

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono to present Erbitux data at ESMO Congress

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen announces PRIME '203' and '181' Phase 3 trial results

Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Researchers discover therapy for treating terminal stages of cancer

Researchers discover therapy for treating terminal stages of cancer

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Terminal metastatic cancer effectively treated in mice

Terminal metastatic cancer effectively treated in mice

Research on immune system paves way to combat mother-to-infant HIV transmission

Research on immune system paves way to combat mother-to-infant HIV transmission

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program

FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program

UAB Comprehensive Cancer Center wins $11.5M grant for pancreatic cancer research

UAB Comprehensive Cancer Center wins $11.5M grant for pancreatic cancer research

Study shows immunotherapy improves survival rate in children with neuroblastoma

Study shows immunotherapy improves survival rate in children with neuroblastoma

New form of immunotherapy increases survival in children with neuroblastoma

New form of immunotherapy increases survival in children with neuroblastoma

HRT therapy can increase breast cancer risk

HRT therapy can increase breast cancer risk

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.